NI201300034A - Conjugado de naloxol - peg cristalino - Google Patents

Conjugado de naloxol - peg cristalino

Info

Publication number
NI201300034A
NI201300034A NI201300034A NI201300034A NI201300034A NI 201300034 A NI201300034 A NI 201300034A NI 201300034 A NI201300034 A NI 201300034A NI 201300034 A NI201300034 A NI 201300034A NI 201300034 A NI201300034 A NI 201300034A
Authority
NI
Nicaragua
Prior art keywords
naloxol
conjugate
peg
crystal
salt forms
Prior art date
Application number
NI201300034A
Other languages
English (en)
Inventor
Leonard Åslund Bengt
Aurell Carl-Johan
Hans Bohlin Martin
Sebhatu Tesfai
Ingvar Ymén Bo
Thomas Healy Eric
Richard Jensen David
Thomas Jonaitis David
Parent Stephan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45893441&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201300034A publication Critical patent/NI201300034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se proporciona conjugados de naloxol - polietilenglicol de fórmula: en formas salinas de tipo oxalato o fosfato, incluidas las formas cristalinas. También se proporcionan métodos para preparar las formas salinas y composiciones farmacéuticas que comprenden las formas salinas.
NI201300034A 2010-09-30 2013-04-01 Conjugado de naloxol - peg cristalino NI201300034A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38850110P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
NI201300034A true NI201300034A (es) 2014-01-23

Family

ID=45893441

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300034A NI201300034A (es) 2010-09-30 2013-04-01 Conjugado de naloxol - peg cristalino

Country Status (39)

Country Link
US (2) US9012469B2 (es)
EP (2) EP2992903B8 (es)
JP (1) JP6034789B2 (es)
KR (1) KR101791724B1 (es)
CN (1) CN103237547B (es)
AR (1) AR083268A1 (es)
AU (1) AU2011307608B8 (es)
BR (1) BR112013007113B1 (es)
CA (1) CA2812649C (es)
CL (1) CL2013000866A1 (es)
CO (1) CO6700851A2 (es)
CR (1) CR20130146A (es)
CU (1) CU24317B1 (es)
DK (1) DK2621496T4 (es)
EA (1) EA023929B1 (es)
EC (1) ECSP13012531A (es)
ES (2) ES2819305T3 (es)
GT (1) GT201300084A (es)
HK (1) HK1187248A1 (es)
HR (1) HRP20151420T4 (es)
HU (1) HUE026726T2 (es)
IL (1) IL225308A0 (es)
ME (1) ME02313B (es)
MX (1) MX2013003587A (es)
MY (1) MY173890A (es)
NI (1) NI201300034A (es)
NZ (1) NZ609874A (es)
PE (1) PE20140636A1 (es)
PL (1) PL2621496T5 (es)
PT (1) PT2621496E (es)
RS (1) RS54488B8 (es)
SA (1) SA111320808B1 (es)
SG (1) SG188474A1 (es)
SI (1) SI2621496T2 (es)
SM (1) SMT201600004B (es)
TW (1) TWI518088B (es)
UA (1) UA112847C2 (es)
UY (1) UY33643A (es)
WO (1) WO2012044243A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24317B1 (es) 2010-09-30 2018-02-08 Astrazeneca Ab Conjugado de naloxol-peg cristalino
CN110615796A (zh) * 2012-10-30 2019-12-27 尼克塔治疗公司 作为阿片激动剂的α-6-mPEG6-O-羟基可酮的固体盐形式以及其用途
US10406152B2 (en) * 2015-03-10 2019-09-10 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种***酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN107303392A (zh) * 2016-04-19 2017-10-31 石家庄蒎格医药科技有限公司 一种聚乙二醇-纳洛酮组合物及应用
EP3544590A4 (en) * 2016-11-23 2020-10-28 Aurobindo Pharma Limited NALOXEGOL OXALATE AND SOLID DISPERSION OF IT
US11373198B2 (en) * 2016-12-02 2022-06-28 Honda Motor Co., Ltd. Evaluation device, evaluation method, and evaluation program
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
CN114137133B (zh) * 2021-12-03 2023-06-09 北京尚修堂医药科技有限公司 一种纳洛醇-peg衍生物有关物质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507136A (en) † 1949-02-19 1950-05-09 New York Quinine And Chemical Alkaloid purification
JPH08504189A (ja) * 1992-09-21 1996-05-07 キン、ボーイ 低／非たんでき性オピオイド鎮痛剤の確認及び使用方法
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
CN1310912C (zh) 2000-12-22 2007-04-18 史密丝克莱恩比彻姆有限公司 5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮甲磺酸盐
MXPA03007392A (es) 2001-02-20 2003-12-04 Enzon Inc Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
MXPA04004026A (es) 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
JP2005507934A (ja) 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
CA2478523A1 (en) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
KR20060120141A (ko) 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. 글리코페질화 에리트로포이에틴
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN102895666B (zh) 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
US8320574B2 (en) * 2006-04-20 2012-11-27 Hewlett-Packard Development Company, L.P. Methods and systems for reducing acoustic echoes in communication systems
WO2007124114A2 (en) 2006-04-21 2007-11-01 Nektar Therapeutics Al, Corporation Stereoselective reduction of a morphinone
EA201100544A1 (ru) * 2006-11-07 2012-01-30 Нектар Терапьютикс Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
CN102573918A (zh) † 2009-07-21 2012-07-11 尼克塔治疗公司 低聚物-阿片样激动剂轭合物
CU24317B1 (es) 2010-09-30 2018-02-08 Astrazeneca Ab Conjugado de naloxol-peg cristalino

Also Published As

Publication number Publication date
PT2621496E (pt) 2016-02-01
SI2621496T2 (sl) 2019-04-30
PE20140636A1 (es) 2014-06-18
RS54488B1 (en) 2016-06-30
AR083268A1 (es) 2013-02-13
CR20130146A (es) 2013-05-15
AU2011307608A8 (en) 2015-08-27
US20150038524A1 (en) 2015-02-05
EA201300423A1 (ru) 2013-09-30
GT201300084A (es) 2015-01-16
PL2621496T5 (pl) 2019-05-31
HRP20151420T1 (hr) 2016-01-29
ES2819305T3 (es) 2021-04-15
EP2621496A1 (en) 2013-08-07
SG188474A1 (en) 2013-05-31
ES2819305T8 (es) 2022-05-26
BR112013007113B1 (pt) 2020-09-24
DK2621496T3 (en) 2016-01-18
US9149539B1 (en) 2015-10-06
CA2812649C (en) 2016-03-01
JP6034789B2 (ja) 2016-11-30
EP2992903B1 (en) 2020-07-15
CN103237547B (zh) 2015-10-07
SI2621496T1 (sl) 2016-02-29
EP2621496B1 (en) 2015-12-16
ES2562643T5 (es) 2019-05-24
TW201307356A (zh) 2013-02-16
MY173890A (en) 2020-02-26
SA111320808B1 (ar) 2014-12-15
CN103237547A (zh) 2013-08-07
AU2011307608B2 (en) 2015-04-09
EP2992903A1 (en) 2016-03-09
CL2013000866A1 (es) 2013-08-30
PL2621496T3 (pl) 2016-05-31
TWI518088B (zh) 2016-01-21
CA2812649A1 (en) 2012-04-05
BR112013007113A2 (pt) 2017-07-25
UA112847C2 (uk) 2016-11-10
NZ609874A (en) 2014-10-31
KR101791724B1 (ko) 2017-10-30
RS54488B8 (sr) 2022-11-30
IL225308A0 (en) 2013-06-27
HK1187248A1 (zh) 2014-04-04
KR20130135844A (ko) 2013-12-11
JP2013538849A (ja) 2013-10-17
AU2011307608B8 (en) 2015-08-27
CO6700851A2 (es) 2013-06-28
UY33643A (es) 2012-04-30
US9012469B2 (en) 2015-04-21
ECSP13012531A (es) 2013-06-28
DK2621496T4 (en) 2019-03-18
ES2562643T3 (es) 2016-03-07
ME02313B (me) 2016-06-20
CU24317B1 (es) 2018-02-08
EP2621496A4 (en) 2014-09-24
US20150283257A1 (en) 2015-10-08
EP2992903B8 (en) 2022-06-08
HUE026726T2 (en) 2016-07-28
HRP20151420T4 (hr) 2019-04-05
AU2011307608A1 (en) 2013-05-02
CU20130047A7 (es) 2013-08-29
EP2621496B2 (en) 2018-12-12
SMT201600004B (it) 2016-02-25
ES2562643T8 (es) 2022-07-12
MX2013003587A (es) 2013-05-31
KR101791724B9 (ko) 2022-06-16
WO2012044243A1 (en) 2012-04-05
RS54488B2 (sr) 2019-03-29
EA023929B1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
NI201300034A (es) Conjugado de naloxol - peg cristalino
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CR20140275A (es) Triazolopiridinas sustituidas
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
UY34418A (es) Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
WO2014152389A8 (en) Imaging agent for detection of diseased cells
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
UY35351A (es) Formulaciones acuosas estables de adalimumab
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
ECSP14013215A (es) Compuestos novedosos
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
EA201490846A1 (ru) Новые производные арилхинолина
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
EA201390799A1 (ru) Триазолопиридины
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
BR112013025236A2 (pt) derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
BR112014009217A2 (pt) antibacterianos à base de fenicol
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
CY1117376T1 (el) Κρυσταλλικο προϊον συζευξης ναλοξολης-peg